HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Steven R. Meyer David B. Ross Ivan M. Rebeyka Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Meyer, S. R. Articles by Campbell, P. M. Search for Related Content PubMed PubMed Citation Articles by Meyer, S. R. Articles by Campbell, P. M. Related Collections Transplantation - heart

J Thorac Cardiovasc Surg 2007;133:1517-1523
© 2007 The American Association for Thoracic Surgery

Surgery for Congenital Heart Disease

Failure of prophylactic intravenous immunoglobulin to prevent sensitization to cryopreserved allograft tissue used in congenital cardiac surgery

^a Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
^b Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
^c Department of Pediatrics, Stollery Children’s Hospital, University of Alberta, Edmonton, Alberta, Canada.

Received for publication October 30, 2006; revisions received December 1, 2006; accepted for publication December 13, 2006.

^_* Address for reprints: Steven R. Meyer, MD, PhD, 4B4.26 Walter Mackenzie HSC, 8440 112 St, Edmonton, Alberta, T6G 2B7 Canada. (Email: srmeyer{at}charter.net).

Objective: Cryopreserved allograft tissue used in the Norwood procedure for infants with hypoplastic left heart syndrome causes profound immunologic sensitization, which may complicate future transplantation. Intravenous immunoglobulin has been shown to reduce sensitization after it has developed, allowing successful transplantation. The purpose of this pilot trial was to determine whether intravenous immunoglobulin given before and after the procedure could prevent sensitization to cryopreserved allograft patches used in the initial repair of hypoplastic left heart syndrome.

Methods: Intravenous immunoglobulin (2 g/kg) was given preoperatively, 3 weeks postoperatively, and 4 months postoperatively to 7 infants undergoing the Norwood procedure. Panel-reactive antibodies were measured with flow cytometry preoperatively and at 1, 4, 6, and 12 months postoperatively and compared with values from a contemporary cohort of 12 infants undergoing the Norwood procedure who did not receive intravenous immunoglobulin.

Results: The groups were well matched for length and weight at time of surgery. Control infants were somewhat younger than the cohort receiving intravenous immunoglobulin (8 ± 5 vs 17 ± 14 days, P = .021). There were no differences in transfusion requirements. There was no difference in the degree of sensitization between control and intravenous immunoglobulin groups at 1 month (class I panel-reactive antibodies 20% ± 30% vs 4% ± 9%, P = .443, class II panel-reactive antibodies 17% ± 27% vs 20% ± 17%, P = .400), 4 months (class I panel-reactive antibodies 62% ± 40% vs 73% ± 41%, P = .813, class II panel-reactive antibodies 49% ± 42% vs 54% ± 41%, P = .706), and 12 months (class I panel-reactive antibodies 49% ± 42% vs 58% ± 39%, P = .686, class II panel-reactive antibodies 44% ± 36% vs 49% ± 42%, P = .651).

Conclusion: Despite studies showing intravenous immunoglobulin to reduce sensitization, we were unable to demonstrate that intravenous immunoglobulin prevented sensitization after exposure to allograft tissue in neonates undergoing congenital cardiac surgery.